India Considers Bulk Drugs Policy Amid Chinese Dependency Concerns
This article was originally published in PharmAsia News
India is concerned about “medicine security” in bulk drug supply as imports from China increasingly dominate the market.
You may also be interested in...
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
Eisai and partner Sun to take lorcaserin off the Indian market. It remains to be seen whether the Japanese firm sees merit in pursuing a simmering patent infringement suit against Dr Reddy’s, which may need to review its own plans for lorcaserin.